Postmenopozal kadınlarda Tibolon’un tolerebilitesi, vajinal kanama oranı ve meme semptomları

Menopozal dönemde estradiol seviyesinde azalma sıklıkla vazomotor semptomlar, uyku bozuklukları, duygu durumunda değisiklikler ve ürogenital atrofi sikayetleri ile beraberdir. Bu dönemdeki sikayetlerin önlenmesinde hormon tedavisi yaygın olarak kullanılmaktadır. Tibolon, postmenopozal kadınlarda endometrium ve memeyi uyarı yapmaksızın kemik, vagina, klimakterik sikayetler, duygu-durum ve seksüel iyilik haline olumlu etkisi olan doku spesifik bir bilesiktir. Çalısmamızda, klimakterik sikayetleri nedeniyle tibolon kullanan hastaların ilaca uyumunu, vajinal kanama oranı ve meme semptomlarını arastırdık. Gereç ve Yöntem : Tedavi rejimi olarak kadınlara sürekli 2.5 mg/gün tibolon baslananlarda, tedavinin 1. ayında ( 1. siklus), 3. ayında (2.ve 3. siklus), ve 6. ayında (5. ve 6. siklus) 3 periyodda değerlendirildi. Toplam 88 postmenopozal (50 doğal menopoz-38 cerrahi menopoz) kadında meme semptomları ve 50 doğal menopozdaki kadında vajinal kanama oranları belirlendi. Bulgular : Kadınların toplam %20’sinde(10/50) vajinal kanama/lekelenme sikayeti oldu. %13 (12/88) kadında memede hassasiyet saptandı. Üç periyod için ortalama VAS skorları sırasıyla; 2.5, 2.3 ve 2.5 olarak bulunmustur. Sonuç : Sonuçlarımız, tibolon ile tedavide yüksek uyum ve düsük vajinal kanama ve meme semptomlarını göstermekte idi.

Anahtar Kelimeler:

Postmenopoz, Hormon replasman tedavisi, Meme, Uterus kanamaları

Effects of tibolone on breast symptoms and vaginal bleeding in postmenopausal women

In the menopausal period, the reduction in the estradiol level is frequently accompanied by symptoms such as vasomotor symptoms, sleep disorders, mood changes and urogenital atrophy. Hormone therapy is commonly used to prevent these symptoms in this period. Tibolone has a positive effect on bone, vagina, climacteric symptoms, mood state, sexual well-being without any induction to the endometrium and breast in the postmenopausal women. In our research we studied the tolerability of the drugs, the ratio of vaginal bleeding and breast symptoms in the patients who use tibolone for climacteric symptoms. Materials and Methods :After the tibolone treatment (2,5 mg/day); the women are evaluated in three periods [first month (1. cycle), third month (2. and 3. cycle) and sixth month(5. and 6. cycle)]. All of 88 postmenopausal women (50 natural menopause -38 surgical menopauses) breast symptoms are determined and in 50 women with natural menapause symptom of vaginal bleeding are determined. Results: 20% of women (10/50) vaginal bleeding/spotting symptoms are occurred. In 13% of women breast tenderness is determined. For three periods’ average VAS scores are determined respectively; 2.5, 2.3 and 2.5. Conclusion: Our results showed that treatment with tibolone is related with high concordance and low vaginal bleeding and breast symptoms.

Keywords:

Postmenopause, Hormone Replacement Therapy, Breast, Uterine Hemorrhage,

PDF

___

1. Te Velde ER, van Leusden HA. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994 ; 343: 654 - 658.
2. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of tolerability in postmenopausal women BJOG 2002; 109: 886 – 893
3. Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990; 35 : 535 – 541.
4. Tang B, Markiewicz L, Kloosterboer HJ, et al. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic / progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 1993; 45: 345 – 351.
5. Kenemans P, Speroff L. Tibolone. Clinical recommendations and practical guidelines: A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21 – 28.
6. Smith Cl, O’malley BW. Coregulator function: a key to understanding tissue spescificity of selective reseptor modulatoors. Endocr Rev 2004; 25: 45 - 71.
7. Gift AG. Visual analogue scales: measurement of subjective phenomena. Nurs Res. 1989 Sep - Oct; 38 (5) : 286 - 288.
8. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006; 20; 53: 413 - 423.
9. Meeuwsen IB, Samson MM, Duursma SA, et al. The influence of tibolone on quality of life in postmenopausal women. Maturitas 2002; 41 : 35 - 43.
10. Egarter C, Fischl F. Tibolon versus konjugierte Ostrogene und Medrogeston in der Behandlung klimakterischer Beschwerden. In: Fischl FH, Huber JC, editors. Menopause: Neue Erkentnisse und Therupiekoniepte. Purkersdorf: Krause & Pachernegg GmbH, 1995: 67 – 74.
11. Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone. Br J Obstet Gynaecol l994; 101: 53-56.
12. Hammar M, Christau S, Nathorst-Boos J, et al. A doubleblind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105: 904 – 911.
13. Archer DF, Hendrix S, Gallagher C, et al. Endometrial effects of Tibolone. J Clin Endocrinol Metab 2006 Dec 27; Baskıda.
14. Lundström E, Christow A, Svane G, et al. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density, Am. J. Obstet. Gynecol. 2002; 186 : 717 – 722.
15. Palomba S, Di Carlo C, Morelli M, et al. Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy, Maturitas 2003; 45 : 267 – 273.
16. Kloosterboer HJ.Tissue-selective effects of tibolone on the breast. Maturitas. 2004 ;49:5-15.
17. Purohit A, Malini B, Hooymans C, et al. Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res 2002; 34 : 1 - 6.
18. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud 1996; 41 : 11 – 15.
19. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998; 5 : 102 – 106.
20. Egarter C, Sator M, Berghammer P, et al. Efficacy, tolerability, and rare side effects of tibolone treatment inpostmenopausal women. Int J Gynaecol Obstet 1999; 64 : 281 - 286.
21. Velthuis-Te Wierik EJ, Hendricks PT, Martinez C. Preferential prescribing of tibolone and combined estrogen plus progesteron therapy in postmenopausal woman. Menopause 2007 Jan 11; Baskıda.